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ABSTRACT OF THE THESIS 
 
Histone and Non-Histone 
Proteins Acetylation Profiles in Breast Cancer 
by 
Alla Karpova 
Master of Science in Biomedical Engineering 
Washington University in St. Louis, 2018 
Research Advisor: Li Ding 
This study evaluates the impact of protein acetylation on breast cancer gene expression and the 
regulation of metabolism. Acetylation is the second abundant post-translational modification after 
phosphorylation, regulating protein activity and function. The alterations in acetylation of both histone 
and non-histone proteins is known to be related to many human diseases, including cancer. 
Acetylation and deacetylation of histones is closely associated with the regulation of gene expression, 
while acetylation of non-histone proteins may have a broad effect on major cellular processes, such as 
proliferation, metabolism, cell cycle and apoptosis, imbalanced regulation of which is essential for 
cancer development. Therefore, it’s critical to explore the role of this post-translational modification 
in cancer in a systematic manner. Here, utilizing a unique acetylome dataset for 120 patients with 
breast cancer, as well as genomic and proteomic data, I showed the impact of acetylation on gene 
expression and metabolic enzymes. More specifically, the association between histone H2B acetylation 
level and expression of FOXA1 and GATA3 transcription factors has been established. In addition, 
acetylation of metabolic enzymes has been demonstrated to reveal additional information on 
metabolism regulation in breast cancer.  
1 
 
 
 
 
 
 
 
1    Background 
1.1    Histone Acetyltransferases and Deacetylases 
Acetylation is one of the most prevalent post-translational modifications (PTMs) in eukaryotic cells 
(Khoury, Baliban, and Floudas 2011). Alongside with phosphorylation, ubiquitination and 
glycosylation, acetylation controls essential cellular processes and mediate the adjustment to changing 
environmental conditions. Constantly developing techniques for protein detection allow for 
identification of thousands of new thousands of PTM sites, leading to a deeper understanding of their 
function (Doll and Burlingame 2015).   
Acetylation can occur in two forms: acetylation of N-terminal (Nt) amino acid in a peptide and 
acetylation of e-amino group of lysines. Unlike Nt-acetylation, lysine acetylation is a reversible 
modification. This modification can be introduced by histone acetyltransferases (HATs) that utilize 
acetyl-coA as a source of acetyl group and transfer it on the e-amino group. Since the acetylation can 
occur not only on histone proteins (as it was thought before), those enzymes are sometimes called 
lysine (K) acetyltransferases (KATs). Histone deacetylases catalyze the reverse reaction and exempt 
lysines from the acetyl group (Fig. 1.1.1). Similar to HATs, they are sometimes called KDACs – lysine 
deacetylases.  
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There are 17 genes encoding proteins with acetyltransferase activity annotated to be the main activity. 
HATs can be subdivided into three families: p300/CBP family, the GNAT family and the MYST 
family. Table 1.1.1 summarizes gene and protein names of major acetyltransferases and provides the 
examples of their substrates.  
 
Figure 1.1.1. Schematic representation of acetylation and deacetylation reactions (Drazic et al. 2016). 
A. N-terminal acetylation of polypeptides. B. Reversible acetylation of e-amino group of lysines. C. 
Reaction specific for NAD+-dependent sirtuins – class of deacetylases. 
 
Table 1.1.1. Human major histone acetyltransferases. 
FAMILY HAT NEW NAME HUGO GENE SYMBOL 
SUBSTRATE 
EXAMPLES 
GNAT HAT1 KAT1 HAT1 H2A, H4 
GNAT GCN5 KAT2A KAT2A H3 
GNAT PCAF KAT2B KAT2B H3, H4, ACLY, PKM 
P300/CBP CBP KAT3A CREBBP H2A, H2B, H3, H4, FOXO1 
P300/CBP P300 KAT3B EP300 H3, FOXO1, SIRT2 
_ TAF1 KAT4 TAF1 H3, H4 
MYST TIP60 KAT5 KAT5 H2A, H4, FOXP3 
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MYST MOZ KAT6A KAT6A H3, H4, p53, RUNX2 
MYST MORF KAT6B KAT6B H3, RUNX2 
MYST HBO1 KAT7 KAT7 H4 
MYST MOF KAT8 KAT8 H4, p53 
GNAT ELP3 KAT9 ELP3 H3, H4, a-tubulin 
_ TFIIIC90 KAT12 GTF3C4 H3 
_ SRC-1 KAT13A NCOA1 H3, H4 
_ SRC-3 KAT13B NCOA3 H3, H4 
_ SRC-2 KAT13C NCOA2 H3, H4 
_ CLOCK KAT13D CLOCK ARNTL, NR3C1 
_ ATF-2 _ ATF2 _ 
 
HATs can localize in different cellular locations. The majority of them functions in the nucleus, such 
as CBP/p300, KAT7, KAT8, HAT1 and others. However, some of the HATs can be found in both 
cytoplasm and the nucleus: CBP/p300, KAT2B, ELP3, ATF2 and CLOCK. In mitochondria, only 
one acetyltransferase (ACAT1) has been identified, modifying pyruvate dehydrogenase complex and 
regulating its activity (Fan et al. 2014). Histone acetyltransferases are almost always associated with 
other protein, defining their target and site specificity. HAT-binding proteins usually contain various 
domains such as bromodomain, chromodomain, WD40 repeats and PHD fingers domains aimed to 
recognize different modifications of histones (Lee and Workman 2007). 
Histone deacetylases can be subdivided into four families: Class I, II and IV require Zn2+ as a cofactor, 
while class III is NAD+- dependent and are called sirtuins. HDACs of class I or II usually modify 
histones, transcription factors and chromatin remodeling complexes (Drazic et al. 2016). However, 
some members of those two classes are also found in cytoplasm (Table 1.1.2). 
Table 1.1.2. Human major histone deacetylases. 
CLASS HDAC COFACTOR COMPARTMENT SUBSTRATE EXAMPLES 
I HDAC1 Zn2+ Nucleus All core histones, RelA, AR 
I HDAC2 Zn2+ Nucleus All core histones 
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I HDAC3 Zn2+ Nucleus All core histones, NF-kB, 
KAT2B, STAT1 
I HDAC8 Zn2+ Nucleus/Cytoplasm All core histones, p53 
II HDAC4 Zn2+ Nucleus/Cytoplasm All core histones, HIF1a, p53 
II HDAC5 Zn2+ Nucleus/Cytoplasm GATA2. GCMa 
II HDAC6 Zn2+ Cytoplasm a-tubulin, HSP90 
II HDAC7 Zn2+ Nucleus/Cytoplasm PLAG1 
II HDAC9 Zn2+ Nucleus/Cytoplasm ATDC 
II HDAC10 Zn2+ Cytoplasm HSP70, PP1 
III SIRT1 NAD+ Nucleus p53, FOXO1, HSF1, KAT7, 
CBP 
III SIRT2 NAD+ Cytoplasm a-tubulin 
III SIRT3 NAD+ Mitochondria GDH, TCA cycle enzymes, 
LCAD, ACSS2 
III SIRT4 NAD+ Mitochondria GLUD1 
III SIRT5 NAD+ Mitochondria CPS1, cytochrome c 
III SIRT6 NAD+ Nucleus H3K56ac, RBBP8 
III SIRT7 NAD+ Nucleolus H3K18ac, PAF53 
IV HDAC11 Zn2+ Nucleus All core histones 
 HDAC1 and HDAC2 share a lot of sequence similarity and involved in regulation of cell cycle and 
apoptosis (Reichert, Choukrallah, and Matthias 2012). HDAC3 is also essential for cell cycle 
regulation, along with DNA damage control (Reichert, Choukrallah, and Matthias 2012). Most of class 
I histone deacetylases are part of bigger protein complexes, such as Sin3, N-CoR/SMRT and 
CoREST, except for HDAC8, which has been determined to function alone (Barneda-Zahonero and 
Parra 2012). In general class I HDACs are expressed ubiquitously in every cell. In contrast to class I, 
class II HDACs are more tissue specific and play crucial role in differentiation and organism 
development. Along with deacetylase domain, class II HDACs have long regulatory domain, allowing 
for binding to tissue specific transcription factors and therefore modulating the specificity of these 
histone deacetylases (M. Parra and Verdin 2010). Sirtuins can be localized in various cellular location, 
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including mitochondria, cytoplasm and the nucleus, where they are involved in regulation of oxidative 
stress, aging, metabolism and DNA repair. 
1.2    Histone Acetylation 
Eukaryotic DNA is wrapped around and packaged with specialized protein complexes, called 
nucleosomes. Each nucleosome is an octamer that consists of four pairs of core histones H2A, H2B, 
H3 and H4. Approximately 147 bp of DNA are wrapped two times around each nucleosome with 8-
114 pb of free DNA linking adjacent nucleosomes. Nucleosome is a basic unit of chromatin, and 
dependent on how tightly packaged the nucleosomes are, chromatin can exist in two basic states: the 
more relaxed euchromatin, and more condensed heterochromatin (Shahbazian and Grunstein 2007). 
The openness of chromatin is thought to directly impact the expression of underlying DNA with 
looser chromatin being more accessible to RNA Pol and transcription factors and more actively 
transcribed. Chromatin structure is highly dynamic, and it plays a crucial role in epigenetic gene 
regulation.  
All core histones have a globular domain that forms the center of the nucleosome and an N-terminal 
tail that protrudes away from the nucleosomes. These N-terminal tails are major sites of nucleosome 
regulation through post-translational modifications (PTMs) including acetylation, phosphorylation, 
methylation, ubiquitination and sumoylation (Shahbazian and Grunstein 2007). All four histones tails 
have lysines – potential sites of methylation or acetylation, and while methylation can be either 
repressing (H3K9me3, H3K27me3), or activating (H3K4me3) depending on the lysine position, lysine 
acetylation is always thought to be activating.  
In vitro studies suggest that lysine acetylation reduces the electrostatic attraction between the 
negatively charged DNA phosphates and positively charged lysines, resulting in a less condensed 
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chromatin. In vivo, lysine acetylation is regulated by “writer” enzymes – histone acetyltransferases 
(HATs) that catalyze the transfer of acetyl group from Acetyl-CoA onto the lysine amino group and 
“eraser” enzymes - histone deacetylases (HDACs) that remove the acetyl group from lysines. HATs 
and HDACs are believed to act non-specifically genome-wide, as well as at individual gene loci when 
targeted by transcription activators and repressors. 
Histone acetylation is dimmed to be always activation mark because it decreases the nucleosome 
affinity to the DNA and increases its accessibility to transcription factors. The most studied histone 
acetylation mark is H3K27Ac, marking active promoters and enhancers (Creyghton et al. 2010; 
Pradeepa 2017). H3K36Ac occurs in RNAP II promoters, while H3K36me3 is usually found within 
exons, marking actively transcribed genes (Morris et al. 2007). H3K9Ac marks the switch from 
transcription initiation to the elongation, in contrast to H3K9me3, which is a strong repressive mark 
of heterochromatin (Gates et al. 2017). H3K14 is critical for DNA damage checkpoint activation (Y. 
Wang et al. 2012), and together with H3K9ac marks bivalent promoters, enhancers and sometimes 
inactive promoters as well (Karmodiya et al. 2012). In one study, a consistent set of histone 
modification has been identified, marking promoter regions. This set contains the following histone 
modifications: H2A.Z, H2BK5ac, H2BK12ac, H2BK20ac, H2BK120ac, H3K4ac, H3K4me1, 
H3K4me2, H3K4me3, H3K9ac, H3K9me1, H3K18ac, H3K27ac, H3K36ac, H4K5ac, H4K8ac and 
H4K91ac. The authors have also shown that promoters containing this marks result in higher gene 
expression than promoters without such modifications. They also noted that the amount of these 
modifications correlate genome wide (Z. Wang et al. 2008). Histone H4 lysine 16 acetylation has 
relatively unusual role not related to regulation of gene expression. H4K16ac controls nucleosome-
level interactions, preventing the formation of evenly spaced nucleosomes, resulting in transcriptional 
repression (Blosser et al. 2009). However, another study has demonstrated that in mouse embryonic 
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stem cells loss of H4K16 acetylation does not affect high-order chromatin structure, and more 
surprisingly that H4K16ac is another marks of active enhancers (Taylor et al. 2013). These findings 
suggest that histones modifications have multifarious functions, depending on the chromatin context, 
developmental stage and cell type.   
1.3    Alterations in Acetylation in Cancer 
It has been recently demonstrated that both HATs and HDACs are required to achieve proper level 
of gene transcription. As it was discussed above, acetylation increases chromatin accessibility to RNAP 
and TFs, however, the fine tuning of acetylation marks on the promoter is required to switch from 
initiation to elongation. In addition, it is very important to balance the level of acetylation at 
transcription start sites, therefore, the activity of both HATs and HDACs is required to achieve right 
transcription rate.  
In general, low acetylation levels can be due to either mutations, low expression, displacement or 
haploinsufficiency of HATs, or overexpression/aberrant recruitment of HDACs, or the combination 
of these events. Similarly, elevated acetylation can be achieved by high expression, mutations and 
aberrant recruitment of HATs or downregulation and mutations in HDACs.  
1.3.1    Wrong Histone Acetyltransferases 
Mutations in HATs have been reported in many cancer types. For example,  CREBBP gene has many 
recurrent mutations in lymphoma and leukemia (Morin et al. 2011; Pasqualucci et al. 2011; Mullighan 
et al. 2011; Gui et al. 2011). In addition, close paralog of CREBBP, gene EP300, was shown to have 
both missense and truncating mutations in solid tumors (Muraoka et al. 1996; Gayther et al. 2000). In 
the TCGA PanCancer study, EP300 was identified as a driver gene (tumor suppressor) for bladder 
(together with CREBBP), endometrial and lung cancers (Bailey et al. 2018). Two functional copies of 
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CREBBP, but not EP300, are required to avoid defects in hematopoietic differentiation, leading to 
malignancies (Kung et al. 2000). Another study on mice proves even more the hypothesis that EP300 
and CREBBP act as tumor suppressors. In this study embryonic stem cells deficient for p300 or CBP 
were inject into mice embryos. These mice were shown to have higher chances to develop 
hematological malignancies compared to control group (Di Cerbo and Schneider 2013). P300 mediates 
the functioning of a number of tumor suppressor proteins, such as TGF-b, p53 and E2F, through 
activation of transcription of target genes (Iyer, Özdag, and Caldas 2004). However, there are clear 
examples of EP300 and CREBBP being oncogenic genes. For instance, both CBP and p300 were 
demonstrated to form fusions with MILL (KMT2A) and MOZ (KAT6A) proteins in the mixed lineage 
leukemia (Di Cerbo and Schneider 2013). In addition, p300/CBP can acetylate more common fusion 
proteins such as AML1-ETO and positively modulate their contribution in leukomogenesis. These 
observations highlight the oncogenic potential of p300/CBP acetyltransferases. Not only mutation 
status alters the function of HATs, but the upregulation of expression level as well. Overexpression 
of p300 was observed in breast, liver and lung carcinomas (Di Cerbo and Schneider 2013), correlating 
with poor prognosis. Moreover, it was demonstrated that p300 promotes the expression of androgen 
receptor (AR) target genes through the acetylation of AR in ligand independent manner in prostate 
cancer (Debes et al. 2003). Therefore, prostate cancer can benefit from high expression of EP300. In 
addition, the knockdown of EP300, but not CREBBP, significantly decreases the proliferation of 
prostate cancer cells. In human breast cancer lines, upon BRCA1 being mutated, p300/CBP acetylates 
estrogen receptor a, and the ectopic expression of WT BRCA1 downregulates p300 (Di Cerbo and 
Schneider 2013). PCAF together with p300 acetylates p53 and increase its DNA binding affinity 
promoting growth arrest and apoptosis (Yamaguchi et al. 2009). Altogether, these results demonstrate 
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that HATs can play both oncogenic and tumor suppressor role in cancer development and their exact 
contribution in each particular cancer type development is still to be identified. 
1.3.2    Wrong Histone Deacetylases 
Similar to HATs, HDACs are also often dysregulated in cancer. The mechanism of dysregulation can 
be very different: from mutations to aberrant recruitment by fusion oncogenic protein. For example, 
class I HDACs are frequently found to be upregulated in breast, pancreatic, lung and prostate 
carcinomas and are almost always associated with poor prognosis (Barneda-Zahonero and Parra 2012). 
In one study, expression of HDAC1 and HDAC3 was correlated with estrogen and progesterone 
receptor expression, suggesting they could be an independent prognostic marker (Krusche et al. 2005). 
In osteosarcoma and breast cancer cells knockdown of HDAC1 results in cell cycle arrest and 
induction of apoptosis (Senese et al. 2007), while the overexpression of HDAC1, HDAC6 and 
HDAC8 increases cell invasion (Park et al. 2011). In addition, in breast cancer cells HDAC2 silencing 
enhances p53 binding ability, which correlates with cell cycle block and senescence induction (Harms 
and Chen 2007). Class II deacetylases were also reported to have mutations and aberrant expression 
in many cancer types (Barneda-Zahonero and Parra 2012). They can also affect cell proliferation rate 
of cancer cells. For instance, HDAC5 induces cell rapid division by regulation of p14 repression 
(Yarosh et al. 2008). In addition, HDAC7 together with estrogen receptor a represses a tumor 
suppressor Reprimo, therefore contributing to cell growth (Malik et al. 2010). HDACs might also be 
involved in developing of cancer chemoresistance: it was shown that DHAC7/HIF-1A complex 
might repress cyclin D1, contributing to chemoresistance (Wen et al. 2010). Not all HDACs function 
as potential oncogenes. In breast carcinomas, HDAC6 expression was demonstrated to be associated 
with better survival and was higher in ER and PR-positive tumors (Zhang et al. 2004). HDAC6 
probably deacetylase Hsp90,  preventing the hormone mediated activation and decreasing the growth 
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of breast cell (Barneda-Zahonero and Parra 2012). Sirtuins are more controversial in terms of their 
impact on cancer development. SIRT3 and SIRT7 were shown to be upregulated in breast cancer, 
while SIRT2 is, on contrary, downregulated in gliomas and gastric carcinomas. SIRT2 appears to act 
as a tumor suppressor ensuring the proper passing of mitotic checkpoint. SIRT3 overexpression 
opposes p53-mediated cell cycle arrest in bladder cancer cells, however, in xenograft models, SIRT3 
knockdown triggers tumorogenesis (Barneda-Zahonero and Parra 2012).  
These results demonstrate that HDACs play important role in cell cycle regulation and are often 
associated with the outcome. However, some findings are contradictory and may vary from cancer 
cell lines to real patients. Hence, it is very important to examine the contribution of every HDAC  
1.3.3   Histone Acetylation in Cancer 
First studies on global histone acetylation changes in cancer cells revealed the overall reduction in 
H4K16 acetylation (Di Cerbo and Schneider 2013). Global loss of H3K18ac, H3K9ac and H4K16ac  
is generally associated with poor prognosis and a shorter life expectation. Moreover, global loss of 
methylation marks such as H3K4me2, H3K9me2 and H3K27me3 is also an indicator of poor 
outcome (Di Cerbo and Schneider 2013). At the same time, another group of researchers associated 
low level of H3K9ac and H3K18ac with a better prognosis in lung cancer (Seligson et al. 2009). The 
molecular mechanisms underlying such changes in global histone modifications level have not been 
established yet. One study has demonstrated that SIRT7 is able to deacetylase H3K18ac, resulting in 
inhibition of key cellular regulators, and that downregulation of SIRT7 contributes to cancer 
proliferation (Barber et al. 2012). Modification of core part of histones might also be dysregulated in 
cancer. For instance, H3K56ac involved in DNA damage response was reported to correlate with de-
differentiated state of cancer cells. So, these are not many things known about global changes in 
histone acetylation and even fewer of them are connected to breast cancer. Nevertheless, global 
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dysregulation of histone acetylation may cause global changes in gene expression patterns, which may 
induce and enhance tumorogenesis.   
1.3.4   Non-histone Proteins Acetylation: Links to Cancer 
Acetylation is implicated in vital cellular processes, many of which have been linked to various diseases, 
including cancer. Acetylation is involved in regulation of gene expression not only in form of histone 
acetylation, but non-histone proteins as well. P53 is a great example of a transcription factor with 
activity modulated by acetylation. This key regulator of cell cycle and apoptosis is acetylation at several 
sites, resulting in enhanced DNA binding capacity and activation of p53-regulated genes. p53 is the 
most important and most frequently mutated tumor suppressor in the majority of cancer type (Narita, 
Weinert, and Choudhary 2018). Another major cellular process often dysregulated in cancer is cell 
cycle. During the cell cycle sister chromatid are grouped together in pairs, which is accomplished by 
cohesion complex. A key component of cohesion complex, SMC3, surrounding chromatids as a ring, 
is acetylated at two sites, therefore resulting in close state of this ring and tight retention of sister 
chromatids together. It was also reported that acetylation modifies the activity of other cell cycle 
regulators such as CDK1, CDK2, Aurora kinase A and B (Narita, Weinert, and Choudhary 2018). 
Taking together, these results suggest that along with phosphorylation acetylation may play important 
role in regulation of cell cycle in both normal and cancer cells. Moreover, acetylation of DNA damage 
response proteins controls the choice of a pathway to repair double-strand breaks: non-homologous 
end-joining (NHEJ) or homology-directed repair (HDR). Acetylation interferes the recruitment of  
NHEJ-promoting factor TP53-binding protein 1 (53BP1) by several means: histone H4 acetylation 
prevents 53BP1 binding to H4K20me2 site; acetylation of H2AK15 decreases the amount of 
H2AK15ub sites and thus impairs 53BP1 recruitment to H2AK15ub; ATM kinase activated upon 
DNA damage response phosphorylates ACLY, thus increasing the production of acetyl-coA in 
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nucleus, resulting in higher histone acetylation and wrong chromatin localization of 53BP1; and finally, 
CBP acetylates 53BP1, which impairs its recruitment to double-strand breaks. Hence, acetylation of 
various proteins defines which pathways will be utilized to repair DSBs. If this decision making 
acetylation is disrupted, NHEJ may be used more frequently, resulted in higher rate of insertions and 
deletions -  common outcome of NHEJ (Narita, Weinert, and Choudhary 2018). Finally, acetylation 
has been shown to be part of cell signaling process as well. For instance, phosphatase PTEN regulating 
the level of PIP3 can be acetylated in its catalytic and C-terminal domains. Acetylation of catalytic 
domain inhibits PTEN activity, while acetylation of C-tail promotes PTEN binding to proteins, 
enhancing its lipid phosphatase activity and recruiting it to signaling complexes (Narita, Weinert, and 
Choudhary 2018). Besides gene transcription, DNA damage response and cell signaling, acetylation is 
also associated with regulation of protein folding, cytoskeleton organization, RNA processing, 
metabolism, autophagy and other vital cellular processes.  
Taking together, acetylation and acetylation regulating enzymes are particularly important for cancer 
formation and are frequently positively or negatively associated with poor outcome. Recent studies by 
the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) have 
produced proteomic, phosphoproteomic and acetylome data for infiltrating breast carcinomas. These 
datasets provide the opportunity to evaluate the impact of acetylation on tumor progression and 
subtyping using a cohort of 122 breast cancer patients. In this study, we characterized global histone 
acetylation profiles and evaluated the differences in metabolic enzymes expression and acetylation 
across breast cancer subtypes. We determined association between acetylation of N-terminal H2B 
histone sites and luminal transcription factors GATA3 and FOXA1. Acetylation of H2B but not other 
histones also significantly correlates with protein expression of many tumor suppressor chromatin 
modifying enzymes, such as KMT2A, KMT2C and KMT2D and this correlation evades in basal and 
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Her2 subtypes. Analysis of acetylation of metabolic enzymes revealed a metabolic uniqueness of basal 
subtype compared to all others and demonstrated that regulation of enzymatic activity by acetylation 
complements of that by gene and protein expression.  
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2    Research Methods 
2.1    Datasets Overview 
2.1.1    Global Acetylome Dataset 
The acetylome dataset for CPTAC Breast cancer was generated by Steven Carr lab, Broad Institute, 
using the targeted LC-MS/MS technology with isobaric tags (TMT (tandem mass tags)-10) (Mertins 
et al. 2018). The peptides were enriched for acetylated lysines, using anti-lysine acetylation antibody 
(Svinkina et al. 2015). The dataset consists of log-ratios of intensities for experimental over common 
reference. The common reference is created by sampling small amount of tissue of every experiment 
sample and mixing them together, ensuring that peptides can be identified more consistently.  
The dataset consists of 9517 detected peptides and 130 tumor samples with eight replicates. Over 
9,000 detected peptides correspond to more than 10,000 unique acetylation sites for more than 300 
proteins. The data were generated in 17 different experiments. Figure 2.1.1.1. shows the distribution 
of detected values for each experiment. Distributions are centered and scaled, so the data is normalized 
for batch effect.  
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Figure 2.1.1.1. Distribution of all detected acetylation values for each experiment separately.  
Samples from one experiment have significantly lower coverage than all other samples (Fig. 2.1.1.2 B) 
and were excluded from the analysis. The minimum coverage for the dataset with excluded samples 
is 26%, the number of peptides with 100% coverage across samples is 1602, corresponding to 744 
genes (Fig. 2.1.1.2 A). 
  
Figure 2.1.1.2. Overview of global acetylome dataset coverage. A. Number of acetylated peptides vs 
coverage. Dashed line indicates the minimal coverage for every peptide in the dataset. B. Distribution 
of coverage of acetylation peptides per sample. Samples with abnormally low coverage were excluded 
from the analysis. 
2.1.2    Global Proteomics Data 
Global proteomics data were downloaded from CPTAC Data Coordinating Center. This includes 122 
tumor samples and 17 adjacent normal samples. The overlap of samples with both acetylome and 
proteome data is 113 tumor samples.  
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2.1.3    Histone Acetylation Dataset 
Four core histones H2A, H2B, H3 and H4 are encoded by a large number of genes, protein products 
of which can differ in one amino acid in N-terminal domain. Mass spectrometry technology is able to 
distinguish different genes of one histone and report two functionally the same sites as separate 
entities. To facilitate the comprehension of the data, I averaged the values for every core histone 
belonging to one functional site. For example, reported peptides HIST1H2BH_K12k and 
HIST1H2BD_K12k were average to obtain a value for H2B_K12 site.  
2.2    Linear Regression Analysis 
2.2.1    Histone Acetylation Linear Model 
Linear model of form 𝐴𝑐#$%& ≈ 	𝛽* +	𝛽, ∗ 𝑃𝑟&0123& + 	𝜀  was fitted using lm function in R to test 
for association between enzyme protein abundance and acetylation level of histone site in 113 tumor 
samples. I used acetylation level of a histone site as a dependent variable and the protein abundance 
of HAT or HDAC as an independent one. The protein level of histones was not included in this 
model since the global proteomic dataset Only Site : Enzyme pairs represented in more than 30 
samples were considered.  The p-value of coefficient 𝛽, were adjusted to FDR using Benjamini-
Hochberg procedure.  
To account for the possibility that such associations may appear by chance, the similar linear models 
were fitted using random pairs of Protein : Ac-site. I randomly selected 50 proteins from the global 
proteomics dataset and 1000 Ac-sites from global acetylome dataset and performed linear regression 
analysis for every pair. I collected the resulted random 𝛽, coefficients and fitted their distribution with 
normal distribution. The resulted distribution was used to obtain the significance level of experimental 
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coefficient given the distribution of random 𝛽,. Only pairs with coefficient p-value under random 
model < 0.05 were considered for further analysis.  
2.2.2    Metabolic Enzymes Acetylation Linear Models 
Similar to histone sites,  associations between HATs and HDACs and acetylation of metabolic 
enzymes we tested using linear model of form: 𝐴𝑐#56#%78%&	#$%& ≈ 	𝛽* +	𝛽, ∗ 𝑃𝑟&0123& + 𝛽9 ∗𝑃𝑟#56#%78%& + 	𝜀 . I used acetylation level of a metabolic enzyme site as a dependent variable and the 
protein abundance of HAT or HDAC and protein abundance of the metabolic enzyme as independent 
ones. The protein level of histones was not included in this model since the global proteomic dataset 
Only Site : Enzyme pairs represented in more than 30 samples were considered.  The p-value of 
coefficient 𝛽, were adjusted to FDR using Benjamini-Hochberg procedure.  
Significant pairs were filtered using random model p-value as described in 2.1.1. 
2.2.3    Normalization of Acetylome Data for Non-histone proteins 
To assess the difference between the amount of protein acetylation independent from protein 
expression level, the global acetylation data were normalized using linear regression of form: 𝐴𝑐#56#%78%&	#$%& ≈ 	𝛽* + 𝛽9 ∗ 𝑃𝑟#56#%78%& + 	𝜀. Protein abundance of any given protein was used as 
an independent variable and the acetylation value of an Ac-site on this protein was used as a dependent 
variable. The residual values  𝜀 of every fitted model was used as a new normalized acetylation value 
not explained by protein abundance.  
18 
 
 
 
 
 
 
2.3    Gene Set Enrichment Analysis 
2.3.1   Sample subset 
To select the samples with high- or low-level acetylation of N-terminal H2B sites, I performed 
Principal Component Analysis on the acetylation data of these sites, using prcomp function in R with 
centering and scaling. Then I used the returned X matrix as input for Optimal_Clusters_KMeans to 
determine the optimal number of k-means clusters and then KMeans_rcpp from ClusterR package. 
The clusters with the highest loadings of histone H2B sites vectors were treated as samples with high 
H2B acetylation, and clusters with the lowest negative loadings were chosen as samples with low H2B 
acetylation. This analysis was done independently for whole sample set and luminal only sample set.  
 
Figure 2.3.1.1. Scorings plot of PCA decomposed matrix of H2B N-terminal acetylation sites. Circle 
indicates a unit circle, the length of Ac-sites vectors is equal to their loading. Cluster 1 is considered 
as high acetylation samples and cluster 3 as low acetylation samples. 
2.3.2    GSEA 
To find gene potentially regulated by histone acetylation, the gene expression data (FPKM), provided 
by (?) was used. Genes with zero expression level were filtered out. Baumgartner-Weiss-Schindler 
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(BWS) test statistic was used as a ranking metric for differentially expressed genes (Zyla et al. 2017). 
The latest release 6.0 of the Network of Cancer Genes database was used as gene sets for GSEA 
(Venkata et al. 2018; Subramanian et al. 2005). GSEA was performed in R using function gsea from 
ClusterProfiler package and BWS statistic as a ranking metric (G. Yu et al. 2012). Only gene sets with 
q-value < 0.05 were considered. Similar analysis was performed with Gene Ontology (GO) sets 
downloaded from MSigDB version 6.2, curated by Broad Institute (Liberzon et al. 2015).  
2.4   Statistical Analysis 
Protein expression and normalized acetylation means in breast cancer subtypes were compared by 
Student’s t-test. The t-test p-values were adjusted to FDR using Benjamini-Hochberg procedure.  The 
differentially expressed metabolic proteins (Fig. 3.2.1.2) and normalized acetylation of metabolic 
proteins sites (Fig. 3.2.2.1) for hierarchical clustering were chosen based on ANOVA test p-value with 
p-value FDR adjusted cutoff 0.05. 
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3    Findings 
3.1    Histone Acetylation  
Acetylome dataset reports ~80 acetylated peptides corresponding to various genes of four canonical 
histones H2A, H2B, H3 and H4. The histone acetylation data have been preprocessed as described in 
section 2.1.3. to facilitate results interpretation. The resulting protein histone acetylation dataset 
contains mostly sites from H2B histones (Fig 3.1).  
 
Figure 3.1.1. Number of acetylated sites per core nucleosome histone reported in the dataset.  
To evaluate general trends in histone acetylation marks across samples and identify general patterns 
in the acetylation of histones, unsupervised clustering of acetylation values has been performed. Figure 
3.1.2 demonstrates the result of the clustering in combination with PAM50 subtype, stage and other 
clinical annotations.  As it seen in Figure 3.1.2, based on the histone acetylation, samples can be 
subdivided into 3 groups: with overall low, average and high acetylation of histones. There is a group 
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of samples, sharing high acetylation of all four core histones; another group shares H3/H4 elevated 
acetylation, while H2A/H2B sites are average; and there are also patients with increased H2B sites 
acetylation, but low H3/H4 acetylation. 
 
 
Figure 3.1.2. Unsupervised clustering of histone acetylation sites. Distance: Euclidean, clustering 
method: Ward’s. Red indicates the highest acetylation level, blue – the lowest, white – the missing 
data. 
 
Additionally, H3 and H4 acetylation sites correlate with each other more than with H2B and H2A 
sites. Indeed, the average Spearman’s correlation value between sites within H3/H4 group is much 
higher than that between them and H2A/H2B group (Fig. 3.1.3). The observed correlation between 
histone sites can be explained by nucleosome structure. Nucleosome assembly is a sequential process, 
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starting from the formation of H2A/H2B and H3/H4 dimers, followed by tetramer and then octamer 
formation.  
 
 
  
Figure 3.1.3. Spearman’s correlation between histone acetylation sites. A. Correlation plot for all 
histone sites. B. Distribution of Rho correlation values for H2A/H2B sites (yellow), or H3/H4 sites 
(green), or between the H2A/H2B and H3/H4 groups.  
 
Many histone sites are known to be involved in transcription regulation and chromatin structure 
maintenance. The acetylation level of some sites may be particularly important for cancer cells and 
therefore tightly regulated. To determine whether there are sites regulated majorly by one of known 
histone acetyltransferases, I used linear regression approach and found histone Ac-sites that can be 
regulated by major acetyltransferases in breast cancer. In this model, Ac-site is an independent variable, 
whereas the protein abundance of an acetyltransferase is a dependent variable:  𝐴𝑐#$%& ≈ 	𝛽* +	𝛽, ∗ 𝑃𝑟&0123& + 	𝜀            [1] 
The bigger 𝛽,, the stronger one unit of enzyme protein abundance affects one unit of the acetylation 
level of an Ac-site. To account for random associations that might appear, the similar regression 
models were fitted with random Ac-sites and random protein abundances. The distribution of resulted 
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linear model coefficients were used to determine the p-value of experimental linear model coefficients.  
Figure 3.1.3 shows the breakdown of linear model coefficients 𝛽, per HAT. As seen from Fig. 3.1.4, 
CREBBP protein product (CBP) demonstrates the strongest association with N-terminal H2B histone 
Ac-sites: H2B K5, K11, K12, K15, K16, K20 and K23. This observation is concordant with a recent 
paper findings, stating that p300/CBP are responsible for acetylation of N-terminal H2B Ac-sites 
(Weinert et al. 2018).  
 
Figure 3.1.4. Coefficients of fitted linear models [1]. Only coefficients with p-value < 0.05 under 
random model are labeled. 
 
EP300 (p300) also shows association with N-terminal H2B Ac-sites, but the coefficients are smaller 
and less significant under the random associations model. In addition, CLOCK, KAT5 and KAT7 
exhibit significant associations with H2AK124, H3K23 and H2BK57 sites, respectively, however the 
physical interaction between these proteins and Ac-sites has not been reported so far. High association 
between KAT7 and KAT8 protein and H2BK5, K11 sites can be accounted to co-expression of these 
acetyltransferases (Spearman’s RhoEP300/KAT7 = 0.6, RhoCREBBP/KAT8 = 0.45).  
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I have decided to focus on CBP : H2B association because H2B sites have better coverage than other 
significant sites, providing more power for statistical tests, and because this histone has never been 
explored in cancer studies. Since acetylation of histones in general decreases the nucleosome positive 
charge, leading to the impaired interaction with DNA phosphate groups and therefore, resulting in a 
more relaxed and accessible chromatin state, global differential acetylation of histone H2B may affect 
the expression of some. One possible mechanism of action on gene expression level might be 
associated with H2A-H2B dimers removal from nucleosomes upon acetylation that may help maintain 
the open state of certain genome regions (Ito et al. 2000). Additionally, at least for yeast, H2B N-
terminal lysines have been shown to be involved in upregulation of genes involved in NAD+ and 
vitamins synthesis (M. A. Parra et al. 2006), suggesting that changes in global histone acetylation can 
influence the expression of specific genes. To determine if differential acetylation of H2B N-terminal 
sites is connected to gene expression, gene set enrichment analysis (GSEA) has been performed using 
RNA-seq gene expression data. I compared gene expression in two groups of samples with either high 
or low acetylation level of H2B N-terminal sites. Using Network of Cancer Genes (NCG) curated 
sets, we identified that ‘Breast cancer’ set is enriched for upregulated genes (high H2B samples 
compared to low H2B ones), along with kidney, bladder and liver cancer types. On the contrary, the 
downregulated genes were found to be enriched for melanoma associated genes (data not shown). 
Since many cancer types share cancer associated protein, such as p53, c-Myc, NRAS and other well-
known oncogenes and tumor suppressors, it is not surprising to see other cancer types to be enriched 
as well. Regardless of other cancer types, breast cancer set shows the biggest number of genes 
contributing to maximum enrichment score (34 genes versus 23 in kidney and 24 in bladder cancer). 
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Figure 3.1.5. Significantly enriched NCG sets in differentially expressed genes. A. Gene ratio of 
enriched sets. B. Running enrichment score for breast and kidney cancer sets. 
 
mRNA and protein expression level of top ten breast cancer associated genes, contributing to the 
maximum enrichment score, are shown in Fig 3.1.6. For these genes the difference in gene expression 
level is translated into the protein level as well.  
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Figure 3.1.6. Top ten 
DE genes enriched for 
breast cancer 
association. mRNA 
level corresponds to 
log2(FPKM + 0.01), 
protein level 
corresponds to 
normalized relative 
protein abundance. 
Significance level of 
Wilcoxon test is 
shown.  
 
 
 
 
Among the top ten breast cancer DE genes, there are three genes involved in the luminal development 
vector establishment in breast tissue: GATA3, FOXA1 and ESR1. Their expression remains high in 
breast cancer subtypes derived from luminal cell types, and positively associated with good outcome 
(Shou et al. 2016; Yoon et al. 2010). Due to subtype specificity, it is possible that the observed 
difference in expression of those genes can be driven by subtype, but not H2B acetylation. To see if 
H2B acetylation shows similar association with GATA3, FOXA1 and ESR1 expression in luminal 
samples only, I tested the mean difference between H2B high and low samples, defined for luminal 
subtypes only, using similar approach (see 2.3.1). It turned out that there is no significant difference 
in GATA3, FOXA1 or ESR1 mRNA level between H2B high and low luminal samples, while GATA3 
and FOXA1 protein level is on contrary significant (p-value <0.05) (See Appendix A Fig. A.1). In 
addition, correlation analysis between H2B Ac-sites and GATA3, FOXA1 and ESR1 mRNA or 
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protein in luminal samples revealed that protein has stronger association with H2B histone than 
mRNA for all three genes (Fig. 3.1.7). However, in all samples together both mRNA and protein 
correlate well with H2B acetylation (Fig A.2). Such dramatic difference in correlation between mRNA 
and H2B acetylation in all samples and luminal samples separately tells us that correlation in all samples 
together is driven by differences between subtypes and not H2B. Protein correlation with H2B 
remains similar for all samples and luminal samples only, suggesting that this correlation is real.  
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Figure 3.1.7. Spearman’s correlation between H2B N-terminal Ac-sites with luminal specific DE 
genes. A. GATA3, mutations are labeled: M – missense mutation, F – frameshift insertion/deletion 
mutation, S – splice site mutation. B. FOXA1, C. ESR1. mRNA level corresponds to log2(FPKM + 
0.01), protein level corresponds to normalized relative protein abundance.  
 
So, we see very low correlation between H2B acetylation and GATA3/FOXA1 mRNA level. 
However, the protein is highly correlated with H2B acetylation. This may indicate that these gene 
products might be regulated on protein level by H2B acetylation. It is known that in the multiprotein 
complexes subunits that are not incorporated in the complex get degraded very soon (Mueller et al. 
2015). GATA3 has been demonstrated to act upstream of FOXA1 and mediate ESR1 binding ability 
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(Theodorou et al. 2013), therefore these proteins may form complexes at  gene regulatory regions. As 
a support for this statement, our data indicates that protein expression of GATA3, FOXA1 and ESR1 
is highly concordant in luminal breast cancer (Fig 3.1.8) - average Spearman’s correlation value 
between protein abundances of these three proteins is 0.41. Hence, these findings suggest us that 
GATA3, FOXA1 and ESR1 form a complex that somehow is linked to H2B acetylation.  
Even though three important transcription factors correlate with H2B acetylation, it is unlikely that 
they directly interact since none of these proteins have a bromodomain able to recognize acetylated 
proteins. Hence, there must be a bromodomain containing mediator able to bind H2B histone sites 
that serves as a linker between the TF and the histone modification. There are at least five proteins 
with a bromodomain that were shown to interact with H2B acetylated lysines: BRD2, BRD3, BRD4, 
CBP (CREBBP gene product) and p300 (EP300 gene product). In luminal breast cancer, all five 
proteins demonstrate good correlation with GATA3 protein and histone H2B acetylation (Fig. 3.1.8 
and Fig. A.3), suggesting that they interact with them and this interaction involves H2B histone.  
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Figure 3.1.8. Unsupervised clustering of histone acetylation sites. Distance: Euclidean, clustering 
method: Ward’s. Red indicates the highest acetylation/protein/mRNA level, blue – the lowest, white 
– the missing data. Mutations are labeled: M – missense mutation, F – frameshift insertion/deletion 
mutation, S – splice site mutation. mRNA level corresponds to log2(FPKM + 0.01), protein level 
corresponds to normalized relative protein abundance.  
 
In fig. 3.1.8, we can clearly see a group of samples with high acetylation of H2B, high protein 
expression of GATA3, FOXA1, ESR1 and bromodomain containing proteins (on the right), and a 
group of samples with low expression of these proteins and low histone acetylation. However, there 
is also a group with elevated acetylation of H2B, but average or sometimes decreased expression of 
transcription factors. One possible explanation to this observation is that other proteins can interact 
with H2B as well, contributing to the longevity of acetylation marks. Such protein can be found by 
similar approach, searching for high protein correlation with H2B acetylation, but low mRNA 
correlation. Such analysis can be done in the future.  
I also noticed that genes that were previously found as differentially expressed between samples with 
high and low H2B acetylation have dramatic differences between their protein and mRNA correlations 
with H2B acetylation. It turned out that in luminal samples these genes corelate with H2B acetylation 
on a protein, but not on a mRNA level. Many of these are chromatin-interacting proteins. This 
indicates the possibility that they are more likely to be involved in interaction with H2B, than to be 
regulated by H2B on the mRNA level (Fig. 3.1.9 A).  Such correlation is not observed for H3 histone 
sites marking active chromatin (Fig. 3.1.9 B), or H2A, or H4 (data not shown).  Among proteins with 
high correlation with H2B there are transcription factors: ARID1A, ARID1B, ARID2, FOXA1, 
GATA3; methyltransferases KMT2A, KMT2C and SETD2; EP300 and other chromatin interacting 
and modifying enzymes. 
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Figure 3.1.9. Average Spearman’s correlation between mRNA and protein levels of differentially 
expressed genes and histones acetylation. A. Correlation computed for H2B K5, K11, K11_K12, 
K15_K16 and K20_K23. B. Correlation computed for H3 K27, K27_K36 and K36. 
  
To sum up, we showed that acetylation of  histone H2B is significantly associated with CBP/p300 
protein level across subtypes, suggesting that CBP/p300 may acetylate H2B N-terminal sites. We also 
demonstrated that in luminal subtypes protein level of  various TFs, including luminal specific TFs, 
correlates with H2B acetylation better than that of  their mRNA level, suggesting the direct or indirect 
interaction between those factors and histone H2B. 
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3.2    Metabolic Proteins Expression and Acetylation 
Interplay 
 
3.2.1    Expression of metabolic enzymes characterize Basal subtype 
metabolism as glycolytic 
Acetylation is the second most common post-translational modification in eukaryotic cells. Along with 
histone proteins, many non-histone proteins have been found to be acetylated as well.  Among 
acetylated proteins, there are ones involved in chromatin remodeling, metabolism, translation, splicing 
and other major vital cellular processes (Choudhary et al. 2009).  Acetylation of non-histone proteins 
has been shown to play essential role in cancer development, therefore it is important to see how the 
acetylation of those proteins can contribute to breast cancer subtyping and development.  
To find out what cellular pathways are enriched for acetylated proteins in the existing acetylome 
dataset for breast cancer, the KEGG pathways enrichment analysis has been performed with 
acetylated proteins reported in the dataset as foreground and the whole list of genes from RNA-seq 
data as a background. The top ten overrepresented KEGG pathways are shown in Fig. 3.2.1.1. Among 
the enriched acetylated pathways there are spliceosome, ribosome, proteasome subunits along with 
enzymes involved in carbon metabolism, amino acid synthesis etc. (Fig. 3.2.1.1). All these gene 
products are housekeeping and relatively abundant in every cell, hence it is not surprising to see them 
enriched for acetylated proteins. This observation points out to one limitation of targeted mass-
spectrometry measurement, which we have to keep in mind, while analyzing the data: less abundant 
proteins may not be captured by antibodies due to their saturation by excessive amount of 
housekeeping proteins.   
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Figure 3.2.1.1 Top enriched pathways for acetylated proteins in breast cancer. The right part provides 
examples of acetylated proteins interactions, colorful nodes indicate that there are novel sites reported 
in the dataset, grey nodes corresponds to proteins with all-known Ac-sites reported in the dataset.  
I have decided to focus on acetylation of cancer metabolism and look for subtype differences in this 
process. Cancer is known to have a rewired metabolism to support constant needs in energy and 
monomers for building new cells. One possible way to reprogram the metabolism is to change the 
expression of metabolic genes. Another way to regulate protein activity without changing the 
expression is to use post-translational modifications. And acetylation is known to be a major regulatory 
modification of metabolic enzymes.  
First, I evaluated how protein expression of metabolic genes is different across subtypes (Fig. 3.2.1.2). 
On figure 3.2.1.2 basal cancer subtype forms an isolated cluster, supporting the fact that basal triple 
negative subtype has a distinctive form of metabolism (Lanning et al. 2017).  
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Figure 3.2.1.2. Unsupervised clustering of protein expression of differentially expressed metabolic 
proteins and carriers (Anova, FDR < 0.05). Distance: Euclidean, clustering method: Ward’s. Red 
indicates the highest protein level, blue – the lowest, white – the missing data.  
Many solute outer membrane carriers are upregulated in basal subtype along with glycolysis enzymes. 
Luminal subtypes and basal subtype tend to have their metabolic proteins regulated in opposite 
manner: highly expressed genes in one subtype are lowly expressed in another one. Her2 cells show 
mixed behavior, but the expression is more concordant with basal subtype, than luminal A/B. 7 out 
of 26 upregulated proteins in basal subtype are involved in glycolysis: glucose importers 
GLUT1/GLUT3, hexokinase HK2/HK3, phosphofructokinase PFKP and enolase ENO1 (t-test 
FDR < 0.05 compared to LumA/B). In addition, lactate dehydrogenase LDHB is also overexpressed 
in basal compared to all other subtypes (t-test FDR < 0.001), suggesting that the final compound of 
glycolysis pyruvate (Pyr) is further transformed into lactate and then exported from the cell by 
Monocarboxylic Acid Transporter 1 (MCT1), which is also upregulated (t-test FDR < 0.01 compared 
to LumA and Her2). Interesting that two out of three enzymes controlling glycolysis rate limiting 
reactions are upregulated (HK and PFKP) in basal, meaning that basal subtype probably has an 
elevated glycolysis flux compared to luminal A and B. I would also like to point out that PFKP gene 
SLC9A1
CRAT
SLC25A1
SLC2A10
G6PD
FASN
ACACA
ACSS3
ME3
SLC9A3R2
SLC44A4
GLUD1
COX17
SLC39A6
SLC9A3R1
FBP1
SLC25A35
ACADS
HMGCL
SLC43A3
SLC52A2
SLC26A6
SLC16A1
SLC5A6
SLC25A19
SLC7A5
SLC3A2
SLC7A1
SLC2A1
SLC2A3
LDHB
PHGDH
PFKP
PSAT1
ENO1
GFPT2
ME2
GLS
NDUFAF7
SLC4A1AP
NDUFAF4
NDUFA4L2
HK2
SLC25A13
SLC25A5
PAM50
Stage
Com
partm
ent
Stage
Stage IA
Stage IIA
Stage IIB
Stage III
Stage IIIA
Stage IIIB
Stage IIIC
PAM50
Basal
LumA
LumB
Her2
Normal_like
Normal
Compartment
cytoplasm
endosome
EPR
Golgi
membrane
mitochondria
nucleus
various
−4
−2
0
2
4
6
35 
 
 
 
 
 
 
in basal subtype has higher copy number variation (CNV) compared to other subtypes, which 
probably causes its upregulated expression (Fig 3.2.1.3). Even though Her2 subtype shows high levels 
of PFKP protein product, the CNV of this gene is not altered in Her2, therefore, another mechanism 
might be involved in the upregulation of protein expression.                     
 
 
 
 
 
 
 
Figure 3.2.1.3. PFKP gene amplification, RNA level and protein level in breast cancer subtypes. Copy 
number level is considered as log2(copy number tumor/ copy number normal). The left plot has a 
dashed line marking 0.5, a cutoff for gene to have one additional copy. FPKM is Fragments Per 
Kilobase of transcript per Million mapped reads.  
 
The same association between CNV, RNA and protein level is observed for GLUT1 and LDHB (Fig. 
A.4 and A.5), but not for HK2/3 (data not shown). Noteworthy, along with upregulation of key 
glycolytic enzymes, basal subtype has significantly reduced protein expression of a key 
gluconeogenesis pathway enzyme - Fructose-1,6-bisphosphatase 1 (FBP1) (t-test FDR < 0.05 
compared to LumA/B), strongly supporting the importance of glycolysis flux for basal subtype.  
Glycolysis is tightly connected to serine synthesis pathway, which starts from glycolysis intermediate 
compound 3-phosphoglycerate (3-PG). Serine synthesis appears to be upregulated in basal subtype as 
well since enzymes controlling first two reactions, phosphoglycerate dehydrogenase (PHGDH) and 
phosphoserine aminotransferase 1 (PSAT1), are upregulated on both RNA and protein levels in basal 
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subtype (t-test FDR<0.05). Next, serine can be used for protein synthesis, or for synthesis of another 
amino acid – glycine. The enzyme catalyzing serine into glycine transformation in cytoplasm – Serine 
Hydroxymethyltransferase 1 (SHMT1) - is slightly downregulated in basal compared to luminal (t-test 
FDR<0.2 compared to LumA/B), while on contrary similar mitochondrial protein is upregulated (t-
test FDR<0.005 compared to LumA/B). Such dysregulation of SHMT1/2 indicates that basal subtype 
may utilize mitochondrial transformation of serine to the glycine more actively as opposed to luminal 
subtypes, which rely on cytoplasmic reaction more. In mitochondria, glycine might be further 
decarboxylated by glycine decarboxylase (GLDC), which is also upregulated in basal breast cancer 
subtype (t-test FDR < 0.05).  
Tumors also often use glutamine as an alternative source of energy to fuel TCA cycle and make citric 
acid required for amino acid synthesis (Scalise et al. 2017). Glutamine can be used for many 
transaminase reactions as a source of amino group. For example, glutamine is utilized by 
Phosphoribosyl Pyrophosphate Amidotransferase (PPAT), catalyzing the first step of purine 
synthesis; Guanine Monophosphate Synthase (GMPS), member of de novo guanine synthesis 
pathway; Glutamine--Fructose-6-Phosphate Transaminase 1/2 (GFPT1/2), controlling the flux of 
glucose into the hexosamine pathway; Asparagine Synthetase (ASNS), transforming aspartate into 
asparagine. All these proteins are upregulated in basal subtype (t-test FDR < 0.05, compared to LumA 
for PPAT; t-test FDR < 0.2, compared to LumA for GFTP1; t-test FDR < 0.05, compared to 
LumA/LumB for GFTP2, GMPS and ASNS). In order for all these reactions to be supported, tumor 
cell should have enough glutamine coming from extracellular space. However, none of known 
glutamine transporters are upregulated in any subtype (SLC1A4, SLC1A5, SLC6A19, SLC38A1, 
SLC38A2), except for SLC6A14, upregulated in Basal and Her2 subtypes on mRNA level (t-test FDR 
< 0.05, compared to LumA/LumB)(Scalise et al. 2017). In addition to being source of amino group 
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for other chemical compounds, glutamine can be hydrolyzed by Glutaminase (GLS), protein 
expression of which is significantly elevated in Basal subtype (t-test FDR < 10-4). Many tumors rely 
on glutamine because it can fuel TCA cycle in mitochondria: first Gln is deaminized into Glu, which 
is further transformed into a-ketoglutarate through reaction catalyzed by Glutamate Dehydrogenase 
1 (GLUD1). As opposed to all other enzymes we have discussed so far, protein level of GLUD1 is 
significantly decreased in Basal subtype (t-test FDR < 0.05), suggesting fueling TCA cycle is not a 
preferable option for this breast cancer subtype.  
3.2.2    Differential acetylation of cytoplasmic and mitochondrial 
metabolic enzymes  
As we see from analysis of  gene and protein expression of  metabolic enzymes, Basal subtype exhibits 
aerobic glycolytic form of  metabolism. In the frame of  glycolytic metabolism, TCA cycle and 
oxidative respiration are usually suppressed (Vander Heiden, Cantley, and Thompson 2009). However, 
protein expression analysis has not revealed any changes in expression of  TCA cycle enzymes in breast 
cancer subtypes. Hence, other mechanisms such as post-translational modifications might be involved 
in balancing mitochondrial reactions.  
Therefore, I evaluated differentially acetylated sites across subtypes. I found 36 metabolic protein with 
differentially acetylated sites, 8 of  which are involved in glycolysis and 9 in TCA cycle. In figure 3.2.2.1 
clustering of  normalized differentially acetylated Ac-sites is shown. Mostly all basal samples have high 
acetylation of  mitochondrial enzymes, while cytoplasmic enzymes are hypoacetylated. A subset of  
luminal A samples has notably elevated acetylation of  glycolytic enzymes such as Glyceraldehyde-3-
Phosphate Dehydrogenase (GAPDH), ENO1, Glucose-6-Phosphate Isomerase (GPI), 
Triosephosphate Isomerase 1 (TPI1), Phosphoglycerate Kinase 1 (PGK1) and Pyruvate Kinase 
(PKM), as well as cytoplasmic paralogs of  TCA cycle enzymes: malate dehydrogenase 1 (MDH1) and 
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Isocitrate Dehydrogenase (NADP+) 1 (IDH1). 
 
Figure 3.2.2.1. Unsupervised clustering of normalized acetylation level of differentially acetylated 
lysines of metabolic proteins and carriers (Anova, FDR < 0.05). Distance: Euclidean, clustering 
method: Ward’s. Red indicates the highest acetylation level, blue – the lowest, white – the missing 
data.  
Interesting that there is a little overlap between differentially expressed and differentially acetylated 
glycolysis enzymes. The summary of observed changes in glycolytic enzymes across subtypes is shown 
in Table 3.2.2.1. 
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Table 3.2.2.1 Summary of protein expression and acetylation of glycolytic enzymes in breast cancer 
subtypes. Number of affected sites was chosen with t-test FDR < 0.1. 
GENE PROTEIN 
EXPRESSION 
ACETYLATION NUMBER OF AC-
SITES 
AFFECTED 
NUMBER OF 
AC-SITES 
DETECTED 
SCL2A1 Higher in basal NA - 0 
SCL2A3 Higher in basal NA - 0 
HK1 No change No change 0 12 
HK2, 3 Higher in basal NA - 0 
GPI No change Lower in basal 6 14 
ALDOA No change Higher in basal 
and her2 
2 12 
ALDOB, C No change NA - 0 
TPI No change Lower in basal 2 13 
GAPDH No change Lower in basal 8 14 
PGK1 No change Lower in basal 9 31 
PGAM1 No change No change 0 8 
ENO1 Higher in basal Lower in basal 7 23 
PKM No change Lower in basal 7 12 
LDHA No change Lower in basal 3 11 
LDHB Higher in basal No change 0 9 
 
All differentially acetylated sites of glycolytic enzymes, except for those of aldolase A (ALDOA), are 
hypoacetylated in Basal subtype. Worth noting that basal subtype differs the most in acetylation of 
metabolic enzymes, but not others (Fig. 3.2.2.2). 
 
Figure 3.2.2.2. Examples of differentially acetylated sites of metabolic enzymes. 
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In Table 3.2.2.2 the summary of changes in acetylation of TCA cycle enzymes and pyruvate 
dehydrogenase complex (PDC) is provided. As it seen from this table none of the TCA cycle proteins 
is differentially expressed, only one subunit DLAT of PDC. However, I found nine mitochondrial 
enzymes with upregulated acetylation in basal subtype.  
Table 3.2.2.2 Summary of protein expression and acetylation of TCA cycle enzymes in breast cancer 
subtypes. Number of affected sites was chosen with t-test FDR < 0.1. 
GENE PROTEIN 
EXPRESSION 
ACETYLATION NUMBER OF AC-
SITES 
AFFECTED 
NUMBER OF 
AC-SITES 
DETECTED 
CS No change No change 0 6 
ACO2 No change Higher in basal 5 15 
IDH2 No change Higher in basal 3 18 
IDH3A,G No change No change 0,0 7,2 
IDH3B No change Higher in basal 2 2 
OGDH No change No change 0 3 
SUCLG1,2 No change Higher in basal 1,1 5,9 
SUCLA2 No change No change 0 3 
SDHA No change Higher in basal  2 8 
SDHB, C No change No change 0 1,0 
FH No change Higher in basal 1 8 
MDH2 No change Higher in basal / 
lower in basal 
3 16 
PDHA1 No change No change 0 5 
PDHB No change Higher in basal 2 3 
DLD No change Higher in basal 1 14 
DLAT Higher in basal No change 0 5 
We identified that glycolysis enzymes are upregulated and hypoacetylated in basal subtype, while TCA 
cycle enzymes are hyperacetylated. Next, I investigated if  there are HATs or HDACs that cause such 
difference between subtypes. 
Hence, I studied the association of  expression of  HATs and HDACs with acetylation of  metabolic 
enzymes. The association was tested using linear model [2]: 
𝐴𝑐#56#%78%&	#$%& ≈ 	𝛽* +	𝛽, ∗ 𝑃𝑟&0123& + 𝛽9 ∗ 𝑃𝑟#56#%78%& + 	𝜀     [2] 
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Deacetylase SIRT3 was found to have strong association with a number of  mitochondrial enzymes 
acetylation sites. SIRT3 is a major deacetylase in mitochondria, for which many TCA cycle enzymes 
were reported to be a substrate (Cimen et al. 2010; W. Yu, Dittenhafer-Reed, and Denu 2012; Ozden 
et al. 2014). SIRT3 shows negative association (as expected for a deacetylase) with MDH2, Acyl-CoA 
Dehydrogenase Very Long Chain (ACADVL), Succinate-CoA Ligase Alpha Subunit (SUCLG1), 3-
Hydroxymethyl-3-Methylglutaryl-CoA Lyase (HMGCL), catalyzing the final step of  leucine 
degradation in mitochondria (Fig. 3.2.2.3). These proteins seem to be under control of  SIRT3 
deacetylase in mitochondria. 
 
Figure 3.2.2.3. Coefficients of  fitted linear models for HDACs [2]. Only coefficients with linear model 
coefficient FDR < 0.1 and p-value < 0.01 under random model are shown. 
 
Linear models for another mitochondrial deacetylase SIRT5 were not significant under FDR cutoff  
and random model p-value cutoff. All other significant associations with negative 𝜷𝟏 seem to be not 
functional because all significant sites are located in mitochondria, while HDACs are either nuclear, or 
cytoplasmic. A number of  positive associations can be explained by high protein coexpression of  a 
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group of  HATs and HDACs (Fig. A.5). At least, HDAC1, HDAC2 and HDAC3 protein correlates 
with the expression of  various HATs. 
Similar to HDACs plot, Fig. 3.2.2.4 is showing significant linear model coefficients for HATs.  
 
Figure 3.2.2.4. Coefficients of  fitted linear models for HATs [2]. Only coefficients with linear model 
coefficient FDR < 0.1 and p-value < 0.01 under random model are shown. 
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and repair (J. Wang et al. 2007). Similar to PGK1, three out four significant MDH1 Ac-sites are 
differentially acetylated in breast cancer subtypes (K107, K118, K236, K239). As a result, linear 
regression analysis can only partially explain differential acetylation of  metabolic enzymes in basal 
subtype compared to LumA/B.  
Not only enzyme concentration can affect the amount of  acetylated protein in cell, but also the 
concentration of  Acetyl-coA, the essential compound for acetyltransferase reaction. Therefore, we 
searched the Acetyl-coA synthesis pathways for any alterations across subtypes (Fig. 3.2.2.5).  
 
Figure 3.2.2.5. Schematic representation of  Acetyl-coA synthesis pathways in basal subtype. Blue 
arrows mean protein downregulation, pink arrows mean protein upregulation, yellow circles – elevated 
acetylation. Adopted from (Narita, Weinert, and Choudhary 2018). ACC1 - Acetyl-CoA Carboxylase 
Alpha, or ACACA; ACC2 - Acetyl-CoA Carboxylase Beta, or ACACB; ACLY - ATP Citrate Lyase, 
ACSS2 - Acyl-CoA Synthetase Short Chain Family Member 2; PDC – Pyruvate Dehydrogenase 
Complex.  
 
There are two pathways for acetyl-coA synthesis in cytoplasm. First one involves ACLY enzyme and 
citric acid, the second one involves ACSS2 enzyme and acetate. Both cytoplasmic acetyl-coA synthesis 
pathways turned out to be downregulated in basal subtype. The main acetyl-coA synthesis enzyme 
ACLY is decreased compared to Her2 (t-test FDR < 0.01), LumB (t-test FDR < 0.08) and LumA (t-
test FDR < 0.2). Similar to ACLY, ACSS2 is slightly diminished in basal compared to all subtypes (t-
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test FDR < 0.2), as well as mitochondrial ACSS3 (t-test FDR < 0.05), but not ACSS1 (t-test FDR < 
0.3) (Fig.3.2.2.6A). In cytoplasm, acetyl-coA serves as a main source of  carbon for fatty acid synthesis. 
However, in basal fatty acid synthesis appears to be downregulated as well. Acetyl-CoA Carboxylase 
Alpha (ACACA) and Fatty Acid Synthase (FASN), catalyzing the first two steps of  fatty acid synthesis 
in cytoplasm, are downregulated on the protein level (ACACA t-test FDR < 0.03, FASN t-test FDR 
< 0.001) (Fig.3.2.2.6B).  Regulatory beta subunit of  Acetyl-CoA Carboxylase Complex (ACACB) is 
decreased only compared to LumA subtype (t-test FDR < 0.01).  
 
Figure 3.2.2.6. Expression of  Acetyl-coA metabolism proteins. A. Protein expression of  proteins 
involved in Acetyl-coA synthesis in cytoplasm. B. Protein expression of  proteins involved in fatty acid 
synthesis from Acetyl-coA in cytoplasm.  
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Such a noticeable downregulation of  Acetyl-coA synthesis and metabolism in cytoplasm can be an 
indicator of  a low concentration of  Acetyl-coA in this compartment, which can in turn explain 
reduced acetylation of  many Ac-sites in cytoplasm. It has been reported that expression of  ACLY can 
predict the level of  histone H2B, H3 and H4 acetylation level (Wellen et al. 2009; Carrer et al. 2017), 
indicating that expression level of  this protein mirrors the concentration of  its reaction product – Ac-
coA, which in turns affect the acetylation of  other proteins. In mitochondria and nucleus, another 
source of  acetyl-coA is active - PDC, catalyzing pyruvate decarboxylation to Ac-coA. All subunits of  
PDC have similar expression level across subtypes, except for DLAT, being significantly upregulated 
in basal (t-test FDR < 0.001 compared to LumB, FDR < 0.15 compared to LumA). Another subunit 
of  PDC, PDHB, was found to be differentially acetylated in basal subtype relatively to LumA/B (Table 
3.2.2.2), but the function of  these sites is unknown. Hence, the local concentration of  Ac-coA in 
mitochondria and nucleus can be maintained by PDC in Basal subtype.  
Taking together we identified possible reasons for such large differences between metabolic enzymes 
acetylation in subtypes. Hypoacetylated state of  cytoplasmic proteins in basal subtype can be partially 
explained by expression of  HATs and supported by possibly decreased level of  cytoplasmic acetyl-
coA. Hyperacetylation of  mitochondrial enzymes in basal is observed probably due to downregulation 
of  mitochondrial SIRT3 deacetylase. 
3.2.3    Functional role of differentially acetylated  
In previous sections, the differences in protein and protein acetylation levels between subtypes have 
been described. If  upregulated expression of  a protein is almost always can be treated as an increased 
rate of  the reaction catalyzed by this protein, post-translational modifications can be as activating, as 
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inhibiting. Hence, there is a need in identification of  functional role of  these sites determined from 
literature.  
The first glycolysis enzyme found with differentially acetylated sites is GPI. The fact that acetylation 
affects its activity has not been reported so far.  However, in 3-dimensional space six out of  fourteen 
detected acetylation sites are differentially acetylated and are located together on one side of  the 
protein surface not interacting with other subunits of  GPI. Four of  them (K252, K447, K454, K524) 
frame a site believed to be important for F-6P binding (Cordeiro et al. 2004; Ji Hyun Lee et al. 2001). 
I hypothesize that acetylation of  lysines surrounding the active site makes it more hydrophobic and 
not preferable for hydrophilic substrate binding. Thus, low acetylation may maintain high enzymatic 
activity. 
 
Figure 3.2.3.1. Localization of  GPI differentially acetylated sites relative to its active center. 
Differentially acetylated sites are marked in pink, not differentially acetylated sites are marked in grey. 
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K519 residue involved in catalysis reported by (Ji Hyun Lee et al. 2001) is marked in magenta. 
Catalytically important sites reported by (Cordeiro et al. 2004) are colored in white.  
 
Similarly, PGK1 has two differentially acetylated sites (K216 and K220) located in proximal distance 
to the substrate binding site. The acetylation of  K220 was determine to decrease enzymatic activity 
by disrupting the binding of  ADP (S. Wang et al. 2015). The 3D conformation of  native PGK1 active 
site can be seen in fig. 3.2.3.2  
 
Figure 3.2.3.2. Localization of PGK1 differentially acetylated sites relative to its active center. 
Differentially acetylated sites are marked in cyan. Substrates 3-PG and ADP are colored in white. 
 
Acetylated sites can interfere not only substrate binding, but also the binding of allosteric regulator as 
it happens in PKM. PKM becomes allosterically activated by fructose-1,6-bisphosphate (FBP) (Lv et 
al. 2013), and K433 acetylation prevents it from binding to PKM, and therefore, reduces the activity 
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of the enzyme. Moreover acetylation of K433 promotes nuclear location of PKM and triggers its 
kinase activity, as opposed to its canonical phosphatase activity in glycolysis (Lv et al. 2013). K433 site 
is differentially lower acetylated in basal subtype, allowing for binding the allosteric regulator and 
keeping glycolytic function of PKM on the required level. 
To sum up, acetylation generally inhibits glycolytic enzymes in different ways. Given the diminished 
acetylation of  Ac-sites in basal subtype, we can conclude that acetylation agrees with protein 
expression in maintaining glycolytic flux on the high level.  
TCA cycle enzymes appear to be regulated by acetylation in a similar fashion. Almost all TCA cycle 
enzymes are subjects to deacetylation by SIRT3 (Sol et al. 2012). For instance, deacetylation of  four 
lysines in SDH complex by SIRT3 was shown to increase its activity (Cimen et al. 2010). Two out of  
four these regulated lysines are differentially acetylated in breast cancer subtypes. Elevated acetylation 
of  K179 and K538 of  SDHA in basal subtype suggests that the function of  this complex is decreased. 
Since SDH is the only unique enzyme acting as part of  both TCA cycle and respiratory chain, we can 
suppose that respiratory chain is also affected by K179 and K538 acetylation. One possible 
explanation why K179 acetylation can inhibit the activity of  SDHA was proposed by Peter Chhoy 
(Chhoy et al. 2016). He postulates that acetylation of  K179 may prevent the binding of  SDHE subunit 
of  SDH complex, which is necessary for loading FAD inside the SDHA subunit.  
Another enzyme MDH2 was shown to have Ac-sites, regulated by SIRT3, as well. One study has 
shown that increased acetylation of  K185, K301, K307 and K314 upon inhibition of  SIRT3 leads to 
the increased activity of  MDH2 towards malate formation (Zhao et al. 2010). On the other hand, 
another study has demonstrated that upon SIRT3 inhibition and calorie restriction, K239 is 
significantly hyperacetylated, leading to the decreased enzymatic activity of  MDH2 (Hebert et al. 
2013). Such change in activity can be explained by K239 residue localization in MDH2 complex. It 
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locates nearby NAD+ binding site and may impair its binding (Figure 3.2.3.3). Interesting that four 
residues reported by Zhao et al. are located together on the outer surface of  MDH2 complex  
 
Figure 3.2.3.3. Localization of  MDH2 differentially acetylated sites. Differentially acetylated 
upregulated in basal sites are marked in pink. Differentially acetylated downregulated in basal sites are 
marked in blue. Not differentially acetylated cites, but previously reported as activating, are in cyan. 
Substrate NAD+ is colored in magenta. 
 
Interesting, K239 was found to be hyperacetylated in basal subtype, but not other four lysines. 
However, it is essential to notice that under normal conditions in mitochondria and low NADH level 
MDH2 catalyzes the reduction of  malate to oxaloacetate, even though the reverse reaction is 
thermodynamically more favorable. In in vitro studies of  MDH2 activity the rate of  reverse reaction is 
always measured, therefore, it is hard to conclude the exact effect of  acetylation on the malate 
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reduction reaction happening in mitochondria. But if  acetylation has the same effect on both forward 
and reverse reactions and K239 acetylation is truly inhibiting, then we can say that MDH2 is less active 
in basal subtype that in others. 
IDH2 has also been reported as SIRT3 substrate. The specific K413 position controlled by SIRT3 
level was stated to be important for IDH2 dimerization required for proper functioning (Zou et al. 
2017). In another study, acetylation mimicking mutagenesis demonstrated that acetylated  K180, K251, 
K256, K272, K275 and K413 decrease the activity of  IDH2 (Xu et al. 2017).  Among these sites, only 
one site K272 was found to be differentially acetylated in the current dataset, not K180, K256, K275 
or K413 (site K251 is not detected). This fact suggests that IDH2 activity may not be decreased in 
basal subtype compared to others. However, there is one site K193, which was not tested in previous 
studies, located in clasp-domain of  IDH2 that is involved in protein dimerization and possible 
tetramerization (Fig. 3.2.3.4). K193 site locates in highly hydrophilic region of  the clasp-domain, and 
acetylation might disrupt its structure since it makes lysines even more hydrophobic. Therefore, 
acetylation of  K193 residue may interfere IDH2 dimer formation that is critical for its proper 
functioning. If  it is so, then basal subtype has IDH2 activity decreased compared to other subtypes. 
 
 
K193 
 
K193 
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Figure 3.2.3.4. Localization of  IDH2 differentially acetylated sites. Differentially acetylated sites are 
marked in pink. Protein is colored by hydrophobicity: red the most hydrophilic, white the most 
hydrophobic. Substrate NADP+ is colored in green. 
Finally, Aconitase ACO2 has been also proved to be SIRT3 substrate along with other TCA cycle 
enzymes. However, the effect of acetylation has been poorly investigated. One study demonstrates 
that upon treatment with acetylating agent, the activity of ACO2 is increasing at low concentration of 
the agent and is pluming at its high concentrations (Fernandes et al. 2015). This controversial behavior 
indicates that either the degree of acetylation is important, or that acetylation of essential for catalysis 
sites is highly not favorable under low concentrations of acetic anhydride. Unfortunately, all four 
differentially acetylated sites are located on the outer surface of ACO2, relatively far from Fe-S cluster 
and substrate binding site, so it is hard to predict if acetylation of those site influences the activity. 
To sum, we identified that the activity of  glycolytic and TCA cycle enzymes is usually diminished upon 
acetylation, therefore, basal breast cancer subtype can be characterized by the increased level of  
glycolysis and decreased level of  TCA cycle. 
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4    Conclusions 
In this work we explored the associations of histone and non-histone proteins acetylation with breast 
cancer subtyping. In luminal A and B subtypes acetylation of N-terminal sites of histone H2B 
significantly correlates with expression level of luminal specific transcription factors FOXA1 and 
GATA3. Moreover, the correlation is higher with protein expression, than with mRNA expression, 
suggesting these factors might be part of complexes interacting with H2B acetylated sites. In addition, 
H2B acetylation correlates with protein expression of a number of tumor suppressor genes, indicating 
that H2B acetylation may be a new prognostic factor in luminal breast cancer. Acetylation of non-
histone proteins can additionally characterize the metabolism of basal subtype. We showed that in 
addition to upregulated expression of glycolysis genes, basal cancer subtype maintains lowered 
acetylation level of cytoplasmic enzymes, but elevated acetylation of mitochondrial enzymes, which 
altogether help cancer favor glycolysis over the TCA cycle. Such differences in acetylation can be 
accounted for differential expression of mitochondrial HDACs and downregulated Ac-coA synthesis 
pathways in basal subtype compared to LumA/B. As a result, hypoacetylated cytoplasmic enzymes 
function more efficiently, while the activity of hyperacetylated mitochondrial enzymes appears to be 
decreased, supporting the established by gene expression vector of aerobic glycolytic metabolism in 
basal subtype of breast cancer.   
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Appendix A 
  
 
 
 
 
 
 
 
Figure A.1. Gene and protein expression of luminal specific DE genes. 
Significance level of Wilcoxon test is shown.  
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Figure A.2. Spearman’s correlation between H2B N-terminal Ac-sites and luminal specific DE genes 
across all subtypes. A. GATA3, mutations are labeled: M – missense mutation, F – frameshift 
insertion/deletion mutation, S – splice site mutation. B. FOXA1, C. ESR1. mRNA level corresponds 
to log2(FPKM + 0.01), protein level corresponds to normalized relative protein abundance.  
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Figure A.3. Spearman’s correlation between H2B interacting bromodomain containing proteins and 
luminal specific DE genes across luminal subtypes. A. GATA3. B. FOXA1. C. ESR1. D. H2B K11 
acetylation. Protein level corresponds to normalized relative protein abundance. 
 
Figure A.4. SCL2A1 gene amplification, RNA level and protein (GLUT1) level in breast cancer 
subtypes. Copy number level is considered as log2(copy number tumor/ copy number normal). The 
left plot has a dashed line marking 0.5, a cutoff for gene to have one additional copy. FPKM is 
Fragments Per Kilobase of transcript per Million mapped reads. 
 
Figure A.5. LDHB gene amplification, RNA level and protein (GLUT1) level in breast cancer 
subtypes. Copy number level is considered as log2(copy number tumor/ copy number normal). The 
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left plot has a dashed line marking 0.5, a cutoff for gene to have one additional copy. FPKM is 
Fragments Per Kilobase of transcript per Million mapped reads. 
 
Figure A.6. Self-correlation of protein expression of HATs and HDACs.  
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